Jie Bai1. 1. Department of Neurology, Tangshan Gongren Hospital Tangshan 063000, Hebei Province, China.
Abstract
OBJECTIVE: To determine the clinical efficacy and safety of urinary Kallindinogenase (HUK) combined with butylphthalide (NBP) in the treatment of progressive cerebral infarction (PCI), to provide more choices for the clinical treatment of PCI. METHODS: The clinical data of 94 with PCI admitted to our hospital from July 2015 to March 2017 were retrospectively analyzed in this study. In addition to basic treatment, the control group (n = 52) was treated with NBP and edaravone. The research group (n = 42) was treated with NBP and HUK. After 14 days of treatment, the clinical efficacy on the two groups was evaluated according to their neurological function deficit using the National Institutes of Health Stroke Scale (NIHSS). The functional recovery results after the stroke were measured using the Modified Rankin Scale (MRS). The independence rate of the two groups was compared. The activities of daily living (ADL) scale was adopted to evaluate the patients' life quality. The two groups were compared in the incidence of complications during treatment and the recurrence within 12 months. RESULTS: The two groups of patients were not greatly different in basic data. After 14 days of treatment, the improvements in NIHSS, MRS, and ADL scores in the research group were more obvious than those in the control group. After 12 months of treatment, the research group showed a significantly higher independence rate than the control group. No serious adverse reactions were found in the two groups. There was no death during the treatment. After 12 months of treatment, the two groups were not greatly different in recurrence rate. CONCLUSION: HUK combined with NBP can reduce the neurological dysfunction and disability rate of patients and improve their independence rate and life quality. It is a safe and effective method for the treatment of PCI. AJTR
OBJECTIVE: To determine the clinical efficacy and safety of urinary Kallindinogenase (HUK) combined with butylphthalide (NBP) in the treatment of progressive cerebral infarction (PCI), to provide more choices for the clinical treatment of PCI. METHODS: The clinical data of 94 with PCI admitted to our hospital from July 2015 to March 2017 were retrospectively analyzed in this study. In addition to basic treatment, the control group (n = 52) was treated with NBP and edaravone. The research group (n = 42) was treated with NBP and HUK. After 14 days of treatment, the clinical efficacy on the two groups was evaluated according to their neurological function deficit using the National Institutes of Health Stroke Scale (NIHSS). The functional recovery results after the stroke were measured using the Modified Rankin Scale (MRS). The independence rate of the two groups was compared. The activities of daily living (ADL) scale was adopted to evaluate the patients' life quality. The two groups were compared in the incidence of complications during treatment and the recurrence within 12 months. RESULTS: The two groups of patients were not greatly different in basic data. After 14 days of treatment, the improvements in NIHSS, MRS, and ADL scores in the research group were more obvious than those in the control group. After 12 months of treatment, the research group showed a significantly higher independence rate than the control group. No serious adverse reactions were found in the two groups. There was no death during the treatment. After 12 months of treatment, the two groups were not greatly different in recurrence rate. CONCLUSION: HUK combined with NBP can reduce the neurological dysfunction and disability rate of patients and improve their independence rate and life quality. It is a safe and effective method for the treatment of PCI. AJTR
Authors: Edward C Jauch; Jeffrey L Saver; Harold P Adams; Askiel Bruno; J J Buddy Connors; Bart M Demaerschalk; Pooja Khatri; Paul W McMullan; Adnan I Qureshi; Kenneth Rosenfield; Phillip A Scott; Debbie R Summers; David Z Wang; Max Wintermark; Howard Yonas Journal: Stroke Date: 2013-01-31 Impact factor: 7.914